
Data from 2 new studies are contributing to the evolution in retinal vein occlusion treatment that first began several years ago. The resear…
from EyewireToday.com
ThromboGenics NV announced that the US Food and Drug Administration has notified the company that its new biologic license application for o…
from EyewireToday.com
Alimera Sciences, Inc., announced the National Authority of Medicines and Health Products (Autoridade Nacional do Medicamento e Produtos de …
from EyewireToday.com
Central serous retinopathy (CSR), or central serous chorioretinopathy (CSC), is an eye disease that causes visual impairment. The condition …
from EyewireToday.com
Patients with age-related macular degeneration (AMD) who do not respond to treatment with intravitreal anti–vascular endothelial growth fa…
from EyewireToday.com
Advanced Cell Technology, Inc. announced that chairman and CEO Gary Rabin will be presenting at the World Stem Cells and Regenerative Medici…
from EyewireToday.com
A device which could restore sight to patients with one of the most common causes of blindness in the developed world is under development i…
from EyewireToday.com
Gene therapy strategies to prevent and treat inherited diseases of the retina that can cause blindness have progressed rapidly. Positive res…
from EyewireToday.com
Ohr Pharmaceutical, Inc., announced that its Squalamine Eye Drops, a potent inhibitor of multiple growth factors implicated in angiogenesis,…
from EyewireToday.com
Using tiny solar-panel-like cells surgically placed underneath the retina, scientists at the Stanford University School of Medicine have dev…
from EyewireToday.com
High-dose ranibizumab (Lucentis) does not provide better visual acuity than standard-dose ranibizumab in newly diagnosed wet age-related mac…
from EyewireToday.com
Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, has announced that positive data from…
from EyewireToday.com
Screening for retinopathy every 2 years instead of the recommended annual screening would be safe and could reduce screening costs by about …
from EyewireToday.com
A subretinal microchip implant has entered new clinical trials in the United Kingdom and Hong Kong, and early results are encouraging, accor…
from EyewireToday.com
Bryn Mawr Communications LLC
1008 Upper Gulph Road, Suite 200
Wayne, PA 19087
Phone: 484-581-1800
Fax: 484-581-1818
Michael Jones
Senior Editor
484-581-1821
mjones@bmctoday.com
Janet Burk
Publisher
214-394-3551
jburk@bmctoday.com
New Retina MD delivers cutting-edge content to retina specialists in their first 15 years of practice. Each issue provides fresh insight from younger physicians plus established mentors on clinical and nonclinical issues affecting ophthalmologists in the earlier stages of their careers. NRMD features surgical pearls, clinical research endeavors, practice management, medical reimbursement and policy, continuing educational requirements, financial planning, innovations, and more.
We use cookies to offer a better user experience and to analyze site traffic. To comply with the European General Data Protection Regulation (GDPR), we are implementing a cookie consent manager to provide residents of the EU/EEA with the ability to customize their cookies. Until this is available, your continued use of this site will be deemed as consent to use of cookies.
Continue »